Prolactinoma medical therapy: Difference between revisions
(Created page with "{{CMG}} {{Prolactinoma}} ==Overview== A '''prolactinoma''' is a benign tumor (adenoma) of the '''pituitary gland''' that produces a hormone called [[prolac...") |
|||
| Line 3: | Line 3: | ||
==Overview== | ==Overview== | ||
A '''prolactinoma''' is a [[benign]] [[tumor]] ([[adenoma]]) of the '''[[pituitary gland]]''' that produces a [[hormone]] called [[prolactin]]. It is the most common type of [[pituitary tumor]]. Symptoms of prolactinoma are caused by too much prolactin in the blood ([[hyperprolactinemia]]) or by pressure of the tumor on surrounding tissues. | A '''prolactinoma''' is a [[benign]] [[tumor]] ([[adenoma]]) of the '''[[pituitary gland]]''' that produces a [[hormone]] called [[prolactin]]. It is the most common type of [[pituitary tumor]]. Symptoms of prolactinoma are caused by too much prolactin in the blood ([[hyperprolactinemia]]) or by pressure of the tumor on surrounding tissues. | ||
==Medical therapy== | |||
[[Dopamine]] is the chemical that normally inhibits prolactin secretion, so doctors may treat prolactinoma with [[bromocriptine]] or [[cabergoline]], drugs that act like [[dopamine]]. This type of drug is called a [[dopamine agonist]]. These drugs shrink the tumor and return prolactin levels to normal in approximately 80% of patients. Both have been approved by the [[Food and Drug Administration]] for the treatment of [[hyperprolactinemia]]. Bromocriptine is the only dopamine agonist approved for the treatment of infertility. Another dopamine agonist, [[pergolide]], is available in the U. S., but is not approved for treating conditions that cause high blood levels of prolactin. | |||
[[Bromocriptine]] is associated with side effects such as [[nausea]] and [[dizziness]]. To avoid these side effects, it is important for bromocriptine treatment to start slowly. | |||
Bromocriptine treatment should not be interrupted without consulting a qualified [[endocrinologist]]. Prolactin levels often rise again in most people when the drug is discontinued. In some, however, prolactin levels remain normal, so the doctor may suggest reducing or discontinuing treatment every two years on a trial basis. | |||
[[Cabergoline]] is also associated with side effects such as [[nausea]] and [[dizziness]], but these may be less common and less severe than with bromocriptine. As with bromocriptine therapy, side effects may be avoided if treatment is started slowly. If a patient's prolactin level remains normal for 6 months, a doctor may consider stopping treatment. Cabergoline should not be interrupted without consulting a qualified endocrinologist. | |||
== References == | == References == | ||
Revision as of 19:30, 21 January 2012
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
|
Prolactinoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Prolactinoma medical therapy On the Web |
|
American Roentgen Ray Society Images of Prolactinoma medical therapy |
|
Risk calculators and risk factors for Prolactinoma medical therapy |
Overview
A prolactinoma is a benign tumor (adenoma) of the pituitary gland that produces a hormone called prolactin. It is the most common type of pituitary tumor. Symptoms of prolactinoma are caused by too much prolactin in the blood (hyperprolactinemia) or by pressure of the tumor on surrounding tissues.
Medical therapy
Dopamine is the chemical that normally inhibits prolactin secretion, so doctors may treat prolactinoma with bromocriptine or cabergoline, drugs that act like dopamine. This type of drug is called a dopamine agonist. These drugs shrink the tumor and return prolactin levels to normal in approximately 80% of patients. Both have been approved by the Food and Drug Administration for the treatment of hyperprolactinemia. Bromocriptine is the only dopamine agonist approved for the treatment of infertility. Another dopamine agonist, pergolide, is available in the U. S., but is not approved for treating conditions that cause high blood levels of prolactin.
Bromocriptine is associated with side effects such as nausea and dizziness. To avoid these side effects, it is important for bromocriptine treatment to start slowly.
Bromocriptine treatment should not be interrupted without consulting a qualified endocrinologist. Prolactin levels often rise again in most people when the drug is discontinued. In some, however, prolactin levels remain normal, so the doctor may suggest reducing or discontinuing treatment every two years on a trial basis.
Cabergoline is also associated with side effects such as nausea and dizziness, but these may be less common and less severe than with bromocriptine. As with bromocriptine therapy, side effects may be avoided if treatment is started slowly. If a patient's prolactin level remains normal for 6 months, a doctor may consider stopping treatment. Cabergoline should not be interrupted without consulting a qualified endocrinologist.